Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - procyclidine hydrochloride - tablet - 5 milligram(s) - tertiary amines; procyclidine

Malta - English - Medicines Authority

aspen pharma trading limited 3016 lake drive city west businees campus dublin 24, ireland - procyclidine hydrochloride - tablet - procyclidine hydrochloride 5 mg - anti-parkinson drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - procyclidine hydrochloride - tablet - 5 milligram(s) - tertiary amines; procyclidine

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - procyclidine hydrochloride - tablet - tertiary amines; procyclidine

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hcl injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.  lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

United States - English - NLM (National Library of Medicine)

iq dental - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride 20 mg in 1 ml - lidocaine and epinephrine injection, usp is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. lidocaine and epinephrine injections is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

United States - English - NLM (National Library of Medicine)

septodont inc. - prilocaine hydrochloride (unii: mjw015baph) (prilocaine - unii:046o35d44r) - prilocaine hydrochloride 40 mg in 1 ml - prilocaine hydrochloride injection, usp, 4% is indicated for the production of local anesthesia in dentistry by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia.

United States - English - NLM (National Library of Medicine)

henry schein - articaine hydrochloride (unii: qs9014q792) (articaine - unii:d3sq406g9x), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - articaine hcl and epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age or older. articaine hcl and epinephrine is contraindicated in patients who are hypersensitive to products containing sulfites. products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people [see warnings and precautions (5.5)]. teratogenic effects - pregnancy category c. there are no adequate and well-controlled studies in pregnant women with articaine hcl and epinephrine. articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (mrhd). articaine hcl and epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the mrhd based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. in contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the mrhd based on body surface area). in pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the mrhd based on body surface area) increased the number of stillbirths and adversely affected passive avoidance, a measure of learning, in pups. this dose also produced severe maternal toxicity in some animals. a dose of 40 mg/kg (approximately equal to the mrhd on a mg/m2 basis) did not produce these effects. a similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring. it is not known whether articaine hcl and epinephrine is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when articaine hcl and epinephrine is administered to a nursing woman. when using articaine hcl and epinephrine, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of articaine hcl and epinephrine (to minimize infant ingestion) and then resume breastfeeding. safety and effectiveness of articaine hcl and epinephrine in pediatric patients below the age of 4 years have not been established. safety of doses greater than 7 mg/kg (0.175 ml/kg) in pediatric patients has not been established. the safety and effectiveness of articaine hcl and epinephrine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered articaine hydrochloride 4% and epinephrine 1:100,000 injections. fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 to 5.1 ml) for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 to 3.9 ml) for complex dental procedures. approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see dosage and administration (2.2)]. in clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received articaine hcl and epinephrine containing epinephrine 1:100,000. among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 to 11.9 ml) were administered to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 to 6.8 ml) were administered to 19 patients for complex procedures. among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 to 11.9 ml) were administered to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 to 5.1 ml) were administered to 4 patients for complex procedures. approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections. no overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. no studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4% and epinephrine 1:100,000 injection in patients with renal or hepatic impairment [see warnings and precautions (5.2)].

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hcl injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.  lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

United States - English - NLM (National Library of Medicine)

civica, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hcl injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.  lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.